louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03355807: Use of MgSO4 for Pain After Bariatric Surgery
Official title: Use of MgSO4 Reduced Opioid Consumption for Pain After Sleeve Gastrectomy Operations: A Prospective Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Therapeutic Opioid Induced Constipation (Disorder)
Keywords: sleeve gastrectomy
magnesium sulfate
postoperative pain
bariatric surgery
Lead sponsor: Yeditepe University Hospital
Sponsor class: OTHER
First posted: 2017-11-28
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The patients undergoing sleeve gastrectomy.
Primary purpose: OTHER

Brief summary: The purpose of this study was to investigate the effect of magnesium sulfate on pain management for pain after sleeve gastrectomy operation

Detailed description: The purpose of this study is to investigate the effect of magnesium sulfate on pain management for pain after sleeve gastrectomy operation.

Design: A prospective, randomized, controlled clinical study.

Setting: University hospital.

Participants: Eighty patients undergoing sleeve gastrectomy.

Measurements and Main Results: Visual analog scale for pain score, sedation score, mean arterial pressure, heart rate, and valid and invalid analgesic demand will record. Serum magnesium levels will determined at preoperative evaluation, postanesthesia care unit admission and at 24 hours. Side effects will also record.

Eligibility criteria: Inclusion Criteria:

* 18 to 65 year old individuals who underwent laparoscopic sleeve gastrectomy.

Exclusion Criteria:

* One or more of the following: cardio - vascular and respiratory diseases, drug and/or alcohol abuse, use of daily an algesia 24 hours before the surgery, renal failure, and liver dysfunction.

Primary outcomes:
measure: Item pain intensity measure assessed by using VAS scores
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: yeditepe universityiversity
name: nurcan kizilcik, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Alvarez A, Singh PM, Sinha AC. Postoperative analgesia in morbid obesity. Obes Surg. 2014 Apr;24(4):652-9. doi: 10.1007/s11695-014-1185-2.
Clinical trial NCT05348707: Impact of Covid-19 on Rhinovirus Epidemic
Official title: Impact of Covid-19 Pandemic on the Epidemiology of Rhinovirus
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Rhinovirus
Keywords: Rhinovirus epidemic
SARS-CoV2/Rhinovirus interaction
Children
Non-pharmacological-interventions
Bronchiolitis
Asthma
Pneumonia
Fever
Meningitis
Rhinovirus infection in children less than 1 years of age
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2022-04-27
Enrollment: 400
Sex: ALL
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Child hospitalized at the " Hopital Femme Mere Enfant ", Lyon, France

- Positive rhinovirus-PCR

Brief summary: Rhinovirus (RV) has long been known as the main etiological agent of "common colds" among children and adults. Indeed, RV is involved in more than 50% of upper respiratory tract infections (URTIs), mostly characterized by nasal congestion, rhinorrhea, sore throat and cough. RV can also cause mild to severe lower respiratory tract infections (LRTIs) such as acute bronchiolitis, pneumonia and exacerbations of underlying chronic lung diseases. RV circulates worldwide, especially in temperate climate zones (i.e. many areas of the USA and Europe) and is responsible for annual outbreaks from early fall to the end of spring.

The covid-19 pandemic in 2020 seemed to interfere with the usual seasonal epidemics. For example, the winter Respiratory Syncytial Virus (RSV) epidemic in Lyon, France, was delayed for several months and reduced by half in terms of incidence of hospitalization cases. This can be explained by the widespread deployment of barrier gestures and social distancing measures, known as "non pharmacological interventions" (NPI).

However, the Covid-19 pandemic doesn't seem to have the same reducing impact on Rhinovirus epidemic. A better understanding of viral interactions and factors influencing RV epidemiology as well as the identification of populations at greater risk are required to improve preventive strategies and reduce the burden of Rhinovirus.


Eligibility criteria: Inclusion Criteria:

* - Child hospitalized at the " Hopital Femme Mere Enfant ", Lyon, France
* Positive rhinovirus-PCR

Exclusion Criteria:

* - parent's refusal to participate

Primary outcomes:
measure: Evolution of the number of children hospitalized for a Rhinovirus-infection in the period of pre Covid-19 pandemic.
timeFrame: From one year before the SARS-CoV-2 pandemic until the beginning of the SARS-CoV-2 pandemic
measure: Evolution of the number of children hospitalized for a Rhinovirus-infection in the period of per-Covid-19 pandemic.
timeFrame: From the beginning of the SARS-CoV-2 pandemic until one year latter
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02764307: Aerosol Delivery in Different Types of Nebulizers
Official title: Evaluation of Aerosol Delivery in Different Types of Nebulizers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthma
Lead sponsor: Chang Gung University
Sponsor class: OTHER
First posted: 2016-05-06
Enrollment: 10
Sex: ALL
Minimum age (years): 20
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Background: Nebulizers design influences efficiency of aerosol delivery. Performance of nebulizers is commonly tested by breathing simulators with static parameters. However, breathing patterns vary in adults.

Objectives: The purpose of this study was to evaluate drug deposition of different types of nebulizers testing with breathing patterns of healthy subjects.

Detailed description: Material and Methods

The study was approved by Chang Gung Memorial Foundation Institutional Review Broad. Ten healthy subjects, aged 20.6±0.5 years, were recruited. Four nebulizers:

1. a constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan);
2. a breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany);
3. a manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan); and
4. a breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) were evaluated.

Eligibility criteria: Inclusion Criteria:

* Healthy college subjects

Exclusion Criteria:

* Currently smoker
* History of asthma
* Drug allergy
* Pulmonary disease
* Heart disease
* Arrythmia
* Hyperthyroids
* Diabetes mellitus
* Lactacidosis
* Pregnant
* Under B-blocker medications

Primary outcomes:
measure: Inhaled and exhaled drug concentrations
timeFrame: Drug deposition was tested Immediately after each nebulization, expected average of 20 minutes
Secondary outcomes:
measure: Breathing parameters
timeFrame: During each nebulization testing, an expected average of 10 minutes
Other outcomes:
Locations:
Study officials:
affiliation: Chang Gung University
name: Hui-Ling Lin, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05697107: Ripretinib in Chinese Patients With Advanced GIST: a Real World Study
Official title: A Large Scale, Multicenter, Real-World Study on Patients With Advanced GIST Receiving Ripretinib
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gastrointestinal Stromal Tumors
Lead sponsor: Peking University
Sponsor class: OTHER
Collaborators: name: First Affiliated Hospital, Sun Yat-Sen University
name: Wuhan Union Hospital, China
name: Sun Yat-sen University
name: Fudan University
name: Xiangya Hospital of Central South University
name: Fujian Medical University Union Hospital
name: The First Affiliated Hospital with Nanjing Medical University
name: First Affiliated Hospital of Zhejiang University
name: First Affiliated Hospital of Chongqing Medical University
name: RenJi Hospital
First posted: 2023-01-25
Enrollment: 308
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Histologically confirmed gastrointestinal stromal tumor

Brief summary: to evaluate the clinical efficacy, safety and predictive factors of ripetinib in Chinese patients with advanced GIST in the real world

Detailed description: Ripretinib has become the standard ≥ 4L treatment in advanced GIST. Given the small sample size of patients in the China bridging study of INVICTUS as well as the short marketing time of ripretinib, further exploration on the long-term efficacy and safety of ripretinib, as well as the dominant gene mutation type of ripretinib in Chinese GIST patients is required. Hence, we plan to further explore the efficacy of ripretinib, predictors of efficacy, etc. by collecting and analyzing real-world data from Chinese patients with advanced GIST recieving ripretinib.

Eligibility criteria: Inclusion Criteria:

-≥18 years old

* Histologically confirmed gastrointestinal stromal tumor (GIST)
* At least one measurable lesion (mRECIST v1.1)
* Received or receiving ripretinib treatment

Exclusion Criteria:

* Patients who received \<1 cycle of ripretinib treatment
* Medical records are incomplete

Primary outcomes:
measure: PFS
timeFrame: approximately 7 months
Secondary outcomes:
measure: DCR
timeFrame: approximately 6 months
measure: OS
timeFrame: approximately 12 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Cancer Hospital
state: Beijing
Study officials:
affiliation: Peking University
name: Lin Shen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04841707: Total-Body Parametric 18F-FDG PET of COVID-19
Official title: Total-Body Parametric 18F-FDG PET of COVID-19
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Covid19
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2021-04-12
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The primary objective is to measure the change between COVID-19 patients and normal subjects; the secondary objective is to measure the change in COVID-19 patients between baseline and 4-month follow up.


Eligibility criteria: Inclusion Criteria:

* COVID-19 positive patients will have a previous positive COVID-19 test and radiographic findings, and/or a positive SARS-CoV-2 antibody test and be in early recovery.
* First PET/CT visit needs to be within 8 weeks of COVID-19 diagnosis.
* Ability to understand and willingness to sign an informed consent form.
* Ability to adhere to the study visit schedule and other protocol requirements.
* All persons ≥18 years of age.

Exclusion Criteria:

* Pregnant or lactating women.
* Any condition that would prohibit the understanding or rendering of informed consent.
* Unable to lie supine for 1-hour imaging with PET.
* Prisoners.
* Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.

Primary outcomes:
measure: BAB permeability assessed
timeFrame: 1 imaging visit up to 60 minutes
Secondary outcomes:
measure: 4 month follow-up PET/CT scan
timeFrame: 1 imaging visit up to 60 minutes
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California, Davis
state: California
Study officials:
affiliation: University of California, Davis
name: Guobao Wang, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00338507: Phase 2 Study - Erdosteine in Patients With CB/COPD
Official title: A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Dose_Ranging Study of Erdosteine for the Treatment of Stable Chronic Bronchitis Associated With Chronic Obstructive Pulmonary Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Bronchitis
Chronic Obstructive Pulmonary Disease
Keywords: Chronic Bronchitis
Chronic Obstructive Pulmonary Disease
Lead sponsor: Adams Respiratory Therapeutics
Sponsor class: INDUSTRY
First posted: 2006-06-20
Enrollment: 400
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This clinical study is designed to explore dose ranging and identify methods to demonstrate the efficacy of Erdosteine in patients with stable Chronic Bronchitis associated with Chronic Obstructive Pulmonary Disease.


Eligibility criteria: Inclusion Criteria:

* Adult patients with a clinical diagnosis of stable CB associated with COPD will be entered into this study. CB is diagnosed clinically in patients who have a documented smoking history and who have a daily productive cough for at least 3 months per year over at least 2 consecutive years in the absence of other causes of chronic cough. COPD is defined by the presence of airflow obstruction from spirometry

Exclusion Criteria:

asthma, bronchiectasis, or cystic fibrosis; active history of lung cancer, respiratory failure, or a need for long-term oxygen therapy;

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: King of Prussia
country: United States
facility: Omnicare Clinical Research
state: Pennsylvania
Study officials:
affiliation: Adams Respiratory Therapeutics
name: Helmut Albrecht, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03874507: Physical Therapy Using Virtual Reality/Augmented Reality
Official title: Technology-Based Intervention for Physical Therapy in Pediatric and Adult Populations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mobility Limitation
Spinal Fusion
Acute Pain
Keywords: virtual reality
augmented reality
physical therapy
deconditioning
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2019-03-14
Enrollment: 41
Sex: ALL
Minimum age (years): 6
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine if non-invasive distracting devices (Virtual Reality (VR) headset, Augmented Reality (AR) Headset) are more effective than the standard of care (i.e., no technology-based distraction) for improving clinical outcomes in patients requiring acute rehabilitation due to deconditioning and surgery. Measures will include include range of motion, gait progression, strength progression, time to first out of bed, time to first step.


Eligibility criteria: Inclusion Criteria:

* Age 6-99
* Diagnosis need for physical rehabilitation

Exclusion Criteria:

* Significant Cognitive Impairment
* History of Severe Motion Sickness
* Current Nausea
* Seizures
* Visual Problems
* Patients whose children are clinically unstable or require urgent/emergent intervention
* Patients who clinically unstable or requires urgent/emergent intervention

Primary outcomes:
measure: Aggregate Movement
timeFrame: Duration of physical therapy, approximately 10 minutes
measure: Patient and Physical Therapist Feedback
timeFrame: Survey of patient and PT satisfaction will be administered after the physical therapy session, duration of survey should take approximately 15 minutes or less
measure: Patient Fatigue
timeFrame: OMNI PRE Questionnaire will be administered after the physical therapy session, duration of questionnaire should take approximately 15 minutes or less
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Lucile Packard Children's Hospital Stanford
state: California
city: Stanford
country: United States
facility: Stanford Health Care Hospital
state: California
Study officials:
References:
citation: Hemphill S, Rodriguez S, Wang E, Koeppen K, Aitken-Young B, Jackson C, Simons L, Caruso TJ. Virtual Reality Augments Movement During Physical Therapy: A Pragmatic Randomized Trial. Am J Phys Med Rehabil. 2022 Mar 1;101(3):229-236. doi: 10.1097/PHM.0000000000001779.
Clinical trial NCT02358707: Is Phonophoresis Treatment Effective?
Official title: Is Phonophoresis Treatment Effective? Determination of Ibuprofen Levels by Microextraction and HPLC (High Liquid Pressure Chromatography) Method in the Tissues of the Patients With Knee Osteoarthritis?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Osteoarthritis, Knee
Keywords: ibuprofen phonophoresis
High performance liquid chromatography
Lead sponsor: Cukurova University
Sponsor class: OTHER
First posted: 2015-02-09
Enrollment: 18
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The specimens from patients as knee osteoarthritis diagnosed who was applied ibuprofen phonophoresis will be analyzed.


Eligibility criteria: Inclusion Criteria:

* having diagnosed as osteoarthritis

Exclusion Criteria:

* surgery at knee
* trauma at knee

Primary outcomes:
measure: level of ibuprofen in bone by Microextraction and HPLC (High Liquid Pressure Chromatography)
timeFrame: 1 year
measure: level of ibuprofen in synovial membrana by Microextraction and HPLC (High Liquid Pressure Chromatography)
timeFrame: 1 year
measure: level of ibuprofen in synovial fluid by Microextraction and HPLC (High Liquid Pressure Chromatography)
timeFrame: 1 year
Secondary outcomes:
measure: Visual Analog Scale (VAS)
timeFrame: 1 year
Other outcomes:
Locations:
city: Adana
country: Turkey
facility: Çukurova Üniversitesi
Study officials:
affiliation: Çukurova University, Faculty of Medicine, Adana
name: Bayram Kelle
role: STUDY_DIRECTOR
References:
Clinical trial NCT04733807: Antibodies Response to mRNA Vaccine Against Covid-19
Official title: Sars-Cov2 Antibodies Response to vaccinE Against covId-19 Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Covid-19
Keywords: vaccine
Covid-19
safety
Sars-Cov2
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
Collaborators: name: ICOT University Hospital
First posted: 2021-02-02
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Health care, administrative, and technical workers of ICOT-Sapienza University Hospital

Brief summary: Vaccine rollout has started in many countries. In Italy, the Covid-19 vaccine used at the moment is the mRNA-based BNT162b2 and is given to Hospital employers. The investigators undertake this study to monitor IgG evolution after vaccination in the participant hospital settings, which includes 500 subjects.

Detailed description: Vaccine rollout has started in many countries. In Italy, the Covid-19 vaccine used at the moment is the mRNA-based BNT162b2 and is given to Hospital employers.

The investigators undertake this observational study to monitor antibody evolution after vaccination in a hospital setting. The primary endpoint is serum IgG at the first month of 2nd jab, and at 3, 6, and 12 months afterward.

As secondary measures, nasopharyngeal swabs are included, at fortnight intervals to detects the spike protein antigen, in the event that putative vaccine inefficacy would expose the health personnel to Covid-19 disease with potential spreading to inpatients.

Further, clinical signs and symptoms are monitored at the weekly interval in the context of adverse reactions/events.

Eligibility criteria: Inclusion Criteria:

* Hospital employers vaccinated against Sars-Cov2

Exclusion Criteria:

* none

Primary outcomes:
measure: Serum IgG antibodies levels in response to vaccine
timeFrame: Serum antibody at 1 month
measure: Serum IgG antibodies levels in response to vaccine
timeFrame: Serum antibody at 3 months
measure: Serum IgG antibodies levels in response to vaccine
timeFrame: Serum antibody at 6 months
measure: Serum IgG antibodies levels in response to vaccine
timeFrame: Serum antibody at 12 months
Secondary outcomes:
measure: Sars-Cov2 infection in vaccinated subjects
timeFrame: up to 12 months
measure: Covid-19 disease in vaccinated subjects
timeFrame: Clinical monitoring of vaccinated subjects through the study completion, an average of 1 year.
Other outcomes:
Locations:
city: Latina
country: Italy
facility: ICOT-Sapienza University Hospital
state: LT
Study officials:
affiliation: University of Roma La Sapienza
name: Luigi Iuliano, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06258707: Bicentric Clinical Investigation to Assess Safety and Performance of LuxBoost IOL
Official title: Bicentric Clinical Investigation to Assess Safety and Performance of a Hydrophobic Acrylic Enhanced Monofocal Intraocular Lens.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Aphakia
Keywords: Enhanced monofocal IOL
Lead sponsor: Cutting Edge SAS
Sponsor class: INDUSTRY
First posted: 2024-02-14
Enrollment: 58
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study purpose is to demonstrate safety and performance of bilateral implantation of LuxBoost intraocular lenses compared with the LuxGood Monofocal lens.

Detailed description: The study purpose is to demonstrate safety and performance after bilateral implantation of LuxBoost intraocular lenses.

The device under investigation is a hydrophobic acrylic monofocal intraocular lens (IOL) manufactured by the sponsor of this study.

Eligibility criteria: Inclusion Criteria:

* Subject aged 50 or over on the day of inclusion, presenting a
* bilateral cataract for which posterior chamber IOL implantation
* has been planned.
* Fit within the available IOL diopter range.
* Have had no previous refractive surgery.
* Regular corneal astigmatism \< 1 dioptre by an automatic
* keratometer (regularity measured by topographer).
* Availability, willingness, and sufficient cognitive awareness to
* comply with examination procedures.
* Ability to attend all study follow-ups.
* Signed informed consent.

Exclusion Criteria:

* Ocular surface disease potentially affecting study results
* Subjects suffering from diagnosed degenerative visual disorders
* Pre-existing ocular pathology
* Acute or chronic disease or illness that would increase risk or confound study results
* Axial lengths and keratometry such as the IOL spherical power is
* not in the range of 14 to 28 D
* Instability of keratometry or biometry measurements
* Amblyopia
* History of ocular trauma or any prior ocular surgery including refractive procedures
* Capsular or zonular abnormalities that may affect postoperative centration or tilt of the lens

Primary outcomes:
measure: Best corrected distance visual acuity (CDVA)
timeFrame: 4/6 months after surgery
Secondary outcomes:
measure: Uncorrected Distance Visual Acuity (UDVA), Uncorrected Intermediate Visual Acuity (UIVA), Distance Corrected Intermediate Visual Acuity (DCIVA), Uncorrected Near Visual Acuity (UNVA), Distance Corrected Near Visual Acuity (DCNVA)
timeFrame: 4/6 months after surgery
measure: Defocus curve
timeFrame: 4/6 months after surgery
Other outcomes:
measure: Patient-reported outcomes
timeFrame: at preoperative visit and 4/6 months after surgery
Locations:
city: Montauban
country: France
facility: Clinique Honore Cave
city: Rennes
country: France
facility: West Optha
Study officials:
affiliation: Clinique Honoré Cave 82000 Montauban
name: Vincent GUALINO
role: PRINCIPAL_INVESTIGATOR
affiliation: Cutting Edge S.A.S (Sponsor)
name: Christophe CESSES
role: STUDY_DIRECTOR
References: